Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

• Status: Completed
• Trial end date: 2016-12-06
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the long-term safety of bimatoprost 0.01% ophthalmic solution compared with bimatoprost 0.03% ophthalmic solution in patients with glaucoma or ocular hypertension.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Bimatoprost; Ophthalmic Solutions; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Ocular hypertension or glaucoma in each eye

• Requires intraocular pressure (IOP)-lowering therapy in both eyes

• Best corrected visual acuity of 20/100 or better in each eye

Exclusion Criteria:

• Ocular seasonal allergies within 2 years

• Required chronic use of ocular medications during the study (intermittent use of artificial tears is allowed)

• Ocular surgery or laser within 3 months

• Anticipated wearing of contact lenses during the study